Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT05900765

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Led by Sun Yat-sen University · Updated on 2023-06-18

54

Participants Needed

1

Research Sites

158 weeks

Total Duration

On this page

Sponsors

S

Sun Yat-sen University

Lead Sponsor

G

Guangzhou Gloria Biosciences Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a multicenter, open-label single-arm phase II study to evaluate the efficacy and safety of Zimberelimab (GLS-010) combined with AVD for newly diagnosed early-stage Hodgkin's lymphoma under the guidance of PET/CT.

CONDITIONS

Official Title

A Study of Zimberelimab(GLS-010) Combined With AVD for Newly Diagnosed Early-stage Hodgkin's Lymphoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosed with primary classical Hodgkin lymphoma confirmed by tissue analysis
  • Disease at stage I or II
  • At least one measurable target lesion according to Lugano 2014 criteria
  • Age 18 to 45 years, or over 60 years (considering fertility and chemotherapy side effects)
  • Performance status (ECOG) of 0 to 3
  • Expected survival of at least 3 months
Not Eligible

You will not qualify if you...

  • Hodgkin's lymphoma of the nodular lymphocyte predominant type
  • Scheduled for autologous stem cell transplantation
  • Contraindications to radiotherapy
  • Central nervous system involvement (meningeal or brain)
  • Contraindications to immune checkpoint inhibitors

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Department of Medical Oncology, Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, China, 510060

Actively Recruiting

Loading map...

Research Team

Z

Zhiming Li

CONTACT

Y

Yu Wang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here